Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04062565 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
A Phase 3 study of Pulmonary Arterial Hypertension, sponsored by University of Arizona.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04062565 is a Phase 3 study of Pulmonary Arterial Hypertension that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 20 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04062565, a Phase 3 study of Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone
Conditions Studied
Interventions
- DRUG Treprostinil Injectable Product
- DRUG Riociguat Pill
Study Locations (1)
Arizona
- University of Arizona - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04062565
The ClinicalTrials.gov registry entry for NCT04062565 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Treprostinil Injectable Product is the first listed.
NCT04062565 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT04062565 about?
NCT04062565 is a clinical study titled "Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH". The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone
What is the current status of trial NCT04062565?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2019-03-25. Estimated completion is 2025-12-31.
What conditions does trial NCT04062565 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT04062565?
The interventions under investigation include: Treprostinil Injectable Product (DRUG), Riociguat Pill (DRUG).
Who is sponsoring clinical trial NCT04062565?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04062565 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
RECRUITING · Phase 3
-
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
ACTIVE NOT RECRUITING · Phase 3
-
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 3
-
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.